HC seeks Novo Nordisk's reply on Natco plea to revoke patent

The Delhi High Court has asked Novo Nordisk to explain why its patent for the diabetes and weight loss drug semaglutide should not be cancelled. Natco Pharma filed the petition. Novo Nordisk's patent expires in March. This has sparked patent disputes as other companies aim to produce their own versions of the drug.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/WFIrpbg
via IFTTT